Infectious endocarditis (IE) is a serious condition characterized by the infection of the heart’s inner lining (endocardium), most commonly involving the heart valves. This relatively rare disease can progress rapidly, leading to significant illness and even death if prompt diagnosis and treatment are not initiated. This article provides an in-depth review of infectious endocarditis, focusing on the critical aspects of diagnosis, evaluation, and current management strategies. Understanding the nuances of Infectious Endocarditis Diagnosis is paramount for healthcare professionals to ensure timely intervention and improve patient outcomes.
Etiology of Infectious Endocarditis
The microbial landscape of infectious endocarditis is dominated by bacteria, with gram-positive cocci being the most frequent culprits. Staphylococcus aureus, streptococci, and enterococci collectively account for the vast majority (80-90%) of cases. Specifically, Staphylococcus aureus is implicated in approximately 30% of cases in developed countries.[1] Beyond these common pathogens, the HACEK group of organisms (Haemophilus, Aggregatibacter (formerly Actinobacillus), Cardiobacterium, Eikenella, and Kingella) and various other bacteria can also cause IE, albeit less frequently. Fungal endocarditis, though rare (around 1% of cases), represents a particularly severe complication, often seen in immunocompromised individuals with systemic Candida or Aspergillus infections.
Identifying the source and setting of infection acquisition – healthcare-associated versus community-acquired – provides valuable clues about the likely causative agent. Healthcare-associated infections are often linked to early prosthetic valve endocarditis (within 60 days post-surgery) or procedures like vascular catheterization, hemodialysis, hospitalization, and cardiac or non-cardiac surgeries. In these scenarios, S. aureus is the predominant pathogen, responsible for about half of nosocomial infections. Coagulase-negative staphylococci, such as S. epidermidis, are commonly associated with indwelling vascular devices or recently implanted prosthetic valves. Enterococcal infections show a similar prevalence in both healthcare and community settings, accounting for roughly 15% and 18% of cases, respectively.[2]
Community-acquired infections often arise in individuals with predisposing conditions such as immunosuppression, intravenous drug use (IVDU), poor dental hygiene, degenerative valve disease, and rheumatic heart disease. IVDU, contributing to almost 10% of IE cases, is associated with repeated introduction of skin flora, primarily S. aureus and S. epidermidis. S. aureus notably exhibits a preference for the tricuspid valve in individuals with IVDU, often affecting otherwise healthy valves. While less frequent in healthcare-associated infections, viridans group streptococci are responsible for approximately 20% of community-acquired IE cases.[3] It’s clinically important to note that Streptococcus gallolyticus (bovis) infections should prompt investigation for underlying colon carcinoma.[4]
Epidemiology of Infectious Endocarditis
Infectious endocarditis remains a rare but significant condition, with an estimated annual incidence ranging from 3 to 10 cases per 100,000 individuals.[5] Historically, males have been disproportionately affected, with a male-to-female ratio of nearly 2:1. The average age of IE patients has increased, now exceeding 65 years. This shift towards older age likely reflects the higher prevalence of risk factors in this demographic, including prosthetic valves, implanted cardiac devices, acquired valvular disease, hemodialysis, and diabetes mellitus.[6] Rheumatic heart disease, once a major risk factor, now accounts for less than 5% of cases in the antibiotic era. Conversely, recreational IVDU is a growing risk factor, now contributing to approximately 10% of all IE cases.[3]
Pathophysiology of Infectious Endocarditis
A healthy, intact endocardium is generally resistant to bacterial colonization. The development of IE typically involves a two-step process: initial endocardial damage followed by bacteremia. Endocardial injury can result from turbulent blood flow around diseased valves or direct trauma from catheters or electrode insertion. In IVDU, repeated valve trauma from injected particulate matter can cause injury.[5] Hemodynamics plays a crucial role, as vegetations preferentially form on the ventricular side of the aortic valve and the atrial side of the mitral valve, areas downstream from regurgitant flow. This suggests that reduced blood flow to the intima may predispose these regions to injury. Furthermore, IE is more common in high-turbulence lesions like small ventricular septal defects or stenotic valves, where high-pressure flow causes more localized damage compared to low-flow defects or those with larger surface areas.[7] Damaged endocardium becomes a site for platelet aggregation and activation of the coagulation cascade, leading to the formation of a sterile, non-bacterial thrombotic vegetation.[8]
Subsequent bacteremia allows for bacterial colonization of these vegetations. Bacteremia can originate from a distant infection or transiently from oral flora introduced during dental procedures or poor oral hygiene. While the minimum bacterial load is not precisely known, experimental studies have induced IE with slow infusions of relatively small amounts of bacteria.[9] Even with endocardial injury and bacteremia, successful pathogenesis requires a virulent organism capable of adhering to and promoting platelet-fibrin deposition. For example, S. aureus produces proteins like clumping factors A and B, and serine-aspartate repeat protein, which independently mediate platelet aggregation. The growing vegetation, composed of platelets and fibrin, effectively shields the pathogens from the host’s immune system, allowing for further bacterial proliferation.[10]
Histopathology of Infectious Endocarditis
Mature vegetations are complex structures comprising inflammatory cells, fibrin, platelets, and erythrocyte debris. The initial platelet-fibrin clot serves as a scaffold for bacterial attachment and further platelet accumulation. Microscopic analysis reveals bacterial biofilms embedded within platelet aggregates. This creates a self-perpetuating cycle where platelets promote bacterial colonization, which, in turn, stimulates further bacterial aggregation via surface protein interactions.[11] In the acute phase, vegetations are avascular. However, as healing begins, neovascularization, fibroblasts, and fibrosis may develop within the affected valve tissue.
The gross and microscopic appearance of valvular tissue varies depending on the infecting organism. Highly virulent pathogens like S. aureus typically induce an intense inflammatory response with a predominance of neutrophils and large bacterial colonies. Macroscopically, the tissue may appear friable with significant destruction. Infections caused by less virulent organisms, such as viridans group streptococci, exhibit a more mononuclear cell-rich inflammatory infiltrate.[12]
Histological staining often reveals focal bacterial colonies. While cultures may be negative after antibiotic initiation, Gram staining of valve tissue remains positive in over 60% of cases even during active treatment.[13] Hematoxylin and eosin staining can identify basophilic cocci in streptococcal and staphylococcal endocarditis. Grocott-Gomori methenamine silver stain, typically used for fungi, can enhance the visualization of streptococci and offers improved bacterial detection in valve tissue compared to Gram stain. Periodic acid-Schiff staining also surpasses Gram stain in sensitivity and effectively highlights the foamy macrophages characteristic of Tropheryma whipplei endocarditis.[12]
In prosthetic valve endocarditis, inflammatory cells tend to be localized to the vegetation on the valve cusp surface. Unlike degenerative valve calcification, which involves macrophages and lymphocytes, prosthetic valve endocarditis is characterized primarily by neutrophilic infiltrates.[14]
History and Physical Examination in Infectious Endocarditis Diagnosis
Clinical presentation of infectious endocarditis is highly variable, ranging from subtle to severe. Clinicians should maintain a high index of suspicion for IE in any patient with risk factors who presents with fever or sepsis of unknown origin.[5] Patients often describe a gradual onset of fever, chills, malaise, and fatigue, typically leading to medical evaluation within a month of symptom onset. Fever, generally defined as a temperature above 38.0°C (100.4°F), is present in over 95% of patients in large studies.[3] However, factors like immunosuppression, advanced age, antipyretic use, or prior antibiotic therapy can suppress fever and reduce its prevalence. Other non-specific systemic infection symptoms such as anorexia, headache, and generalized weakness may also be present. Cardiopulmonary symptoms such as chest pain, dyspnea, reduced exercise tolerance, orthopnea, and paroxysmal nocturnal dyspnea are less common but should raise suspicion for underlying aortic or mitral valve insufficiency. Acute valvular incompetence can manifest with sudden onset heart failure symptoms, representing a medical emergency.
Patient history often reveals predisposing conditions and risk factors crucial for infectious endocarditis diagnosis. Current or past indwelling catheters, IVDU, recent pacemaker implantation, or prosthetic valves are significant risk factors indicating potential endocardial injury.[5] Inquiry about known degenerative valve disease, such as calcific aortic stenosis or mitral valve prolapse, is important as these conditions underlie approximately 30% of IE cases.[3, 15] While rheumatic heart disease is less prevalent today in developed countries, it remains a relevant consideration. Diabetes mellitus is a common comorbidity in IE patients in North America.
Physical examination may reveal classic stigmata of IE and signs of peripheral embolization complications. Fever is common, and tachypnea and tachycardia may occur in the context of valvular insufficiency or systemic infection. Hypotension can develop due to septic or cardiogenic shock in cases of acute valve perforation. A new or worsening heart murmur, while classically associated with IE, is present in less than 50% of cases; however, its identification aids in localizing valve involvement. Pulmonary rales may be auscultated in cases of severe mitral or aortic regurgitation. Dermatologic findings, such as Osler nodes (painful nodules on пальцы and toes), splinter hemorrhages (subungual linear reddish-brown streaks), and Janeway lesions (painless hemorrhagic macules on palms and soles), are classic but individually observed in less than 10% of cases.[3] Abdominal examination may reveal splenomegaly or signs of peritonitis, suggesting bowel perforation from mesenteric artery occlusion. Neurological examination may detect focal motor or sensory deficits indicative of intracerebral embolization affecting specific vascular territories.
Evaluation and Diagnostic Criteria for Infectious Endocarditis Diagnosis
Patients presenting with symptoms suggestive of endocarditis often have non-specific complaints like fatigue, fever, or chest pain. These symptoms overlap with various serious conditions, necessitating a broad diagnostic approach. In cases of chest pain or dyspnea, it is crucial to initially consider and rule out other life-threatening cardiopulmonary conditions such as acute coronary syndrome, pulmonary embolism, and pneumonia. Patients presenting with overt sepsis should undergo rapid, protocol-driven evaluation and management.
For patients with chest pain or dyspnea, an initial 12-lead electrocardiogram (ECG) is a rapid and cost-effective tool to assess for underlying ischemia, arrhythmias, or structural heart disease. ECG findings in IE are often normal. ST-segment elevation can occur but should primarily raise suspicion for myocardial infarction, even in patients with known IE, and managed accordingly.[16, 17] A chest X-ray (two views) can reveal pulmonary abscesses, infiltrates, or pleural effusions. In severe left-sided valvular insufficiency, signs of cardiopulmonary edema, cardiomegaly, or cephalization of pulmonary vessels may be evident. Further investigation for pulmonary parenchymal disease, empyema, or arterial embolization may require advanced imaging such as contrast-enhanced computed tomography (CT) or CT angiography. Cardiac biomarkers are essential in patients with suspected myocardial ischemia or myocarditis to evaluate for myocardial injury.
In the acute setting, comprehensive laboratory testing is often warranted due to the non-specific nature of presenting symptoms. A complete blood count (CBC) may show leukocytosis, suggestive of infection. Subacute or chronic presentations may exhibit normocytic anemia consistent with anemia of chronic disease. Inflammatory markers like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated in approximately 60% of cases, although non-specific.[3] A basic metabolic panel (BMP) should be obtained to identify electrolyte imbalances requiring immediate correction.
Following the exclusion of more critical conditions, the diagnosis of infectious endocarditis relies on microbiological and echocardiographic evidence of infection, guided by the Modified Duke Criteria. These criteria are categorized into major and minor criteria, and diagnosis requires fulfillment of specific combinations: two major criteria, one major and three minor criteria, or five minor criteria.
The first major criterion is confirmation of bacteremia. The Modified Duke Criteria specify two separate blood cultures positive for typical IE pathogens, such as viridans group streptococci, S. gallolyticus, HACEK organisms, S. aureus, or community-acquired enterococci, in the absence of a primary infection focus. If less common pathogens are suspected, persistent bacteremia is required, defined as either two positive cultures drawn more than 12 hours apart or positive results from the majority of at least three or more separate cultures (with the first and last samples drawn at least one hour apart).[18] The American Heart Association (AHA) update also recognizes a single positive blood culture for Coxiella burnetii or an anti-phase 1 IgG antibody titer ≥ 1:800 as meeting this criterion.[19]
The second major criterion is echocardiographic evidence of endocardial involvement. Echocardiography must demonstrate a mobile intracardiac mass attached to a valve, supporting structure, or implanted material. Transthoracic echocardiography (TTE) is typically the initial imaging modality. However, the AHA recommends transesophageal echocardiography (TEE) for enhanced sensitivity and specificity if clinical suspicion for IE remains high despite a negative TTE (Class I, Level of Evidence B).[19] TEE is particularly valuable in situations where TTE visualization is limited, such as in patients with chronic obstructive pulmonary disease, prior thoracic surgery, obesity, or prosthetic valves.
The five minor criteria are:
- Predisposing conditions: pre-existing valvular abnormalities, structural heart disease, IVDU.
- Fever: temperature > 38°C (100.4°F).
- Vascular phenomena: mycotic aneurysms, intracranial hemorrhage, Janeway lesions, major arterial emboli, septic pulmonary infarcts.
- Immunologic phenomena: Osler’s nodes, Roth spots, glomerulonephritis, positive rheumatoid factor.
- Microbiological evidence: positive blood cultures not meeting major criterion or serological evidence of active infection consistent with IE.[19]
Treatment and Management of Infectious Endocarditis
Effective treatment aims to eradicate endocardial vegetations and minimize secondary complications. Patients presenting with acute decompensated heart failure, septic shock, or stroke require immediate stabilization and resuscitation, prioritizing airway, breathing, and circulation. Subsequent management involves prolonged courses of bactericidal antibiotics and consideration of cardiothoracic surgical intervention.
Antibiotic selection and duration depend on the valve involved and the antibiotic susceptibility of the infecting organism. For native valve endocarditis caused by penicillin-susceptible viridans group streptococci or S. gallolyticus, a short two-week regimen of ceftriaxone 2 g IV every 24 hours plus gentamicin 3 mg/kg IV every 24 hours is a proposed option.[19] [Class IIa, Level of Evidence B] Other regimens include ceftriaxone 2 g IV every 24 hours for four weeks or aqueous penicillin G 12-18 million units IV every 24 hours (continuous infusion or divided doses). Prosthetic valve endocarditis due to these organisms typically requires a minimum 6-week course with higher penicillin G doses (24 million units/24 hours) or ceftriaxone 2 g with or without gentamicin 3 mg/kg every 24 hours.
Staphylococcal infections often necessitate extended antibiotic therapy. For native valve methicillin-sensitive S. aureus (MSSA) IE, 6-week courses of nafcillin 2 g every four hours or cefazolin 2 g every 8 hours are recommended. Methicillin-resistant S. aureus (MRSA) infections are typically treated with vancomycin 15 mg/kg every 12 hours or daptomycin 8 mg/kg daily for 6 weeks. Dual gentamicin therapy is no longer recommended for MSSA or MRSA IE due to lack of benefit and renal toxicity.[19, 20] Prosthetic valve staphylococcal IE management is similar but requires the addition of rifampin and gentamicin. For prosthetic valve MSSA IE, gentamicin 3 mg/kg IV in 2-3 divided doses plus rifampin 900 mg IV in 2-3 divided doses every 24 hours for 2 and 6 weeks respectively, are added to the nafcillin regimen. MRSA prosthetic valve IE should receive the same gentamicin and rifampin regimen in addition to vancomycin.[19, 21]
Enterococcal IE, both native and prosthetic valve, requires combination antibiotic regimens due to beta-lactam monotherapy’s lack of bactericidal activity against enterococci. Examples include ampicillin or penicillin G plus an aminoglycoside like gentamicin for 4-6 weeks. Interestingly, a dual beta-lactam regimen of ampicillin plus ceftriaxone can achieve bactericidal activity against Enterococcus faecalis and may be used.[22] Penicillin resistance necessitates vancomycin-gentamicin combination therapy; however, emerging resistance to penicillin, gentamicin, and vancomycin may require alternative agents like linezolid or daptomycin.
Antimicrobial treatment guidelines are constantly evolving and should be regularly reviewed. Early infectious disease consultation is highly recommended to guide antibiotic therapy. Serial blood cultures (every 24-48 hours) should be obtained to confirm bloodstream infection clearance and guide ongoing antimicrobial therapy.[19]
Surgical intervention, including valve repair or replacement, is generally indicated in cases of acute heart failure, extensive infection with localized complications, and recurrent arterial embolization. Acute valvular compromise causing heart failure often warrants surgery within 24 hours. AHA/ACC guidelines also recommend early surgery before completing antibiotic therapy in cases of atrioventricular block, paravalvular abscess, or destructive lesions.[23] [Level IB] Preventing and treating recurrent embolic events is a major indication for surgery. Early surgery is recommended for patients with recurrent emboli or large, mobile native valve vegetations (>10 mm).[23] Studies show that antimicrobial therapy alone reduces stroke incidence in IE.[24] Early surgical intervention (within 48 hours) has been shown to significantly reduce in-hospital mortality and the risk of embolic events.[25] Currently, approximately half of all IE cases undergo surgical intervention due to these benefits.[3]
Differential Diagnosis of Infectious Endocarditis
A broad differential diagnosis should be considered in the evaluation of suspected infectious endocarditis, encompassing infectious, inflammatory, neoplastic, and mechanical etiologies. The differential will vary based on presenting symptoms. For chest pain, consider acute coronary syndrome, acute heart failure, aortic dissection, myopericarditis, pulmonary embolism, pneumonia, and empyema. In patients with prosthetic valves, perivalvular thrombosis (especially with anticoagulation interruption) or suture dehiscence should be considered. Recurrent arterial emboli post-myocardial infarction may suggest ventricular mural thrombus. Atrial myxoma should be considered in young patients with new murmurs. Non-bacterial thrombotic endocarditis (NBTE) associated with sterile valvular thrombi can occur in malignancy (marantic endocarditis) or systemic lupus erythematosus (Libman-Sacks endocarditis).[26]
Prognosis of Infectious Endocarditis
Prognosis in infectious endocarditis is variable and depends on factors such as pathogen virulence, secondary complications, pre-existing conditions, and native versus prosthetic valve involvement. In-hospital mortality is around 18%, with one-year mortality reaching up to 40%.[27] Prosthetic valve endocarditis within 60 days of surgery carries the highest in-hospital mortality (around 30%). Staphylococcus infection and heart failure are significant predictors of in-hospital mortality.[28] Surgical intervention, while performed in nearly 50% of cases, does not appear to independently increase in-hospital mortality risk.[3]
Complications of Infectious Endocarditis
Infectious endocarditis can lead to various intracardiac and extracardiac complications. Acute valvular incompetence, causing heart failure, occurs in about one-third of cases, resulting from valve perforation or damage to chordae tendineae or papillary muscles. Mitral or tricuspid regurgitation can lead to atrial enlargement and arrhythmias like atrial fibrillation. Less common intracardiac complications include abscesses (14%) and atrioventricular blocks (8%).[3]
Peripheral embolization can cause significant extracardiac complications. Right-sided vegetations can lead to pulmonary emboli manifesting as pulmonary abscesses, pneumonia, empyema, or pulmonary infarcts. Neurologic complications are the most severe and frequent extracardiac sequelae, affecting 15-30% of cases.[3] These include ischemic stroke, intracranial hemorrhage, meningitis, cerebral abscess, and mycotic aneurysms. Ischemic strokes, typically from embolized mitral/aortic vegetations, are the most common neurologic complication.[29] Septic embolization to vasa vasorum can weaken vessel walls, leading to mycotic aneurysms, which are often asymptomatic until rupture.[30]
Less frequent complications include acute renal failure from immune-mediated glomerulonephritis or embolic infarction. Splenic infarcts and abscesses, particularly with S. aureus infection, can occur. Acute mesenteric ischemia with bowel necrosis and perforation is a serious complication of arterial embolization.
Deterrence and Patient Education for Infectious Endocarditis
Antibiotic prophylaxis recommendations remain somewhat controversial, but AHA/ACC guidelines recommend prophylaxis for certain high-risk individuals undergoing high-risk procedures. Patients with prosthetic cardiac valves, prosthetic material for valve repair, prior IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with residual valvular insufficiency, or cardiac transplants with valve dysfunction should receive antibiotic prophylaxis before dental procedures involving mucosal perforation or gingival/periapical tissue manipulation.[23] Prophylactic regimens include amoxicillin 2 g or clindamycin 600 mg (for beta-lactam allergy) administered within 60 minutes before the procedure.[20] Current guidelines do not recommend prophylaxis for cutaneous, genitourinary, or gastrointestinal procedures.
Enhancing Healthcare Team Outcomes in Infectious Endocarditis Management
Effective management of infectious endocarditis requires a multidisciplinary approach. Early involvement of an interprofessional team including cardiology, cardiothoracic surgery, infectious diseases, and primary care providers is crucial for optimal patient care.[31] While antibiotics are the mainstay of treatment, surgical consultation is essential for intracardiac complications or peripheral embolization. Patients with IVDU-associated IE should receive inpatient counseling and access to outpatient addiction treatment services.[32] Early infectious endocarditis diagnosis and guideline-directed management are key to reducing morbidity and mortality associated with this serious condition.
Review Questions
(Original article includes review questions here. For SEO purposes and per instructions, these are omitted in this revised version. If needed, review questions can be added back in, focusing on infectious endocarditis diagnosis and related topics.)
References
1.Barnett R. Infective endocarditis. Lancet. 2016 Sep 17;388(10050):1148. PubMed: 27672723
2.Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods MC, Peetermans WE. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J. 2007 Jan;28(2):196-203. PubMed: 17158121
3.Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH., International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009 Mar 09;169(5):463-73. PMC free article: PMC3625651 PubMed: 19273776
4.Abdulamir AS, Hafidh RR, Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. 2011 Jan 20;30(1):11. PMC free article: PMC3032743 PubMed: 21247505
5.Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016 Feb 27;387(10021):882-93. PubMed: 26341945
6.Correa de Sa DD, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, Bachuwar A, Pazdernik M, Steckelberg JM, Wilson WR, Baddour LM. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2010 May;85(5):422-6. PMC free article: PMC2861970 PubMed: 20435834
7.RODBARD S. HEMODYNAMIC CONSIDERATIONS IN ENDOCARDITIS. Med Sci. 1964 Jan;15:43-9. PubMed: 14103624
8.Durack DT, Beeson PB, Petersdorf RG. Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol. 1973 Apr;54(2):142-51. PMC free article: PMC2072580 PubMed: 4700697
9.Veloso TR, Chaouch A, Roger T, Giddey M, Vouillamoz J, Majcherczyk P, Que YA, Rousson V, Moreillon P, Entenza JM. Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis. Infect Immun. 2013 Mar;81(3):697-703. PMC free article: PMC3584864 PubMed: 23250949
10.O’Brien L, Kerrigan SW, Kaw G, Hogan M, Penadés J, Litt D, Fitzgerald DJ, Foster TJ, Cox D. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol. 2002 May;44(4):1033-44. PubMed: 12010496
11.Jung CJ, Yeh CY, Shun CT, Hsu RB, Cheng HW, Lin CS, Chia JS. Platelets enhance biofilm formation and resistance of endocarditis-inducing streptococci on the injured heart valve. J Infect Dis. 2012 Apr 01;205(7):1066-75. PubMed: 22357661
12.Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory Diagnosis of Infective Endocarditis. J Clin Microbiol. 2017 Sep;55(9):2599-2608. PMC free article: PMC5648697 PubMed: 28659319
13.Morris AJ, Drinkovic D, Pottumarthy S, Strickett MG, MacCulloch D, Lambie N, Kerr AR. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. Clin Infect Dis. 2003 Mar 15;36(6):697-704. PubMed: 12627353
14.Lepidi H, Casalta JP, Fournier PE, Habib G, Collart F, Raoult D. Quantitative histological examination of bioprosthetic heart valves. Clin Infect Dis. 2006 Mar 01;42(5):590-6. PubMed: 16447102
15.Nakagawa T, Wada H, Sakakura K, Yamada Y, Ishida K, Ibe T, Ikeda N, Sugawara Y, Ako J, Momomura S. Clinical features of infective endocarditis: comparison between the 1990s and 2000s. J Cardiol. 2014 Feb;63(2):145-8. PubMed: 23906529
16.Berk WA. Electrocardiographic findings in infective endocarditis. J Emerg Med. 1988 Mar-Apr;6(2):129-32. PubMed: 3385174
17.Nazir S, Elgin E, Loynd R, Zaman M, Donato A. ST-Elevation Myocardial Infarction Associated With Infective Endocarditis. Am J Cardiol. 2019 Apr 15;123(8):1239-1243. PubMed: 30890259
18.Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. PubMed: 10770721
19.Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA., American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. PubMed: 26373316
20.Hoen B, Duval X. Clinical practice. Infective endocarditis. N Engl J Med. 2013 Apr 11;368(15):1425-33. PubMed: 23574121
21.Kafetz K, Atkin N. Diagnosing dying in the acute hospital setting. Clin Med (Lond). 2009 Aug;9(4):398-9; author reply 399. PMC free article: PMC4952520 PubMed: 19731420
22.Gavaldà J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A, de la Torre-Cisneros J, Peña C, Martínez-Lacasa X, Sarria C, Bou G, Aguado JM, Navas E, Romeu J, Marco F, Torres C, Tornos P, Planes A, Falcó V, Almirante B, Pahissa A. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007 Apr 17;146(8):574-9. PubMed: 17438316
23.Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, Rigolin VH, Sundt TM, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. PubMed: 28298458
24.Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter F, Tornos P, Verhagen DW, Cabell CH., ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007 Dec;154(6):1086-94. PubMed: 18035080
25.Kang DH, Kim YJ, Kim SH, Sun BJ, Kim DH, Yun SC, Song JM, Choo SJ, Chung CH, Song JK, Lee JW, Sohn DW. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012 Jun 28;366(26):2466-73. PubMed: 22738096
26.Kaufmann CC, Wessely E, Huber K. Non-bacterial thrombotic endocarditis in the context of pulmonary adenocarcinoma: a case report. Eur Heart J Case Rep. 2020 Feb;4(1):1-5. PMC free article: PMC7047059 PubMed: 32128491
27.Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ, Woods CW, Reller LB, Ryan T, Fowler VG. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002 Jan 14;162(1):90-4. PubMed: 11784225
28.Ohara T, Nakatani S, Kokubo Y, Yamamoto H, Mitsutake K, Hanai S., CADRE investigators. Clinical predictors of in-hospital death and early surgery for infective endocarditis: results of CArdiac Disease REgistration (CADRE), a nation-wide survey in Japan. Int J Cardiol. 2013 Sep 10;167(6):2688-94. PubMed: 22805554
29.Jawad K, Kroeg G, Koziarz A, Lehmann S, Dieterlen M, Feder S, Garbade J, Rao V, Borger M, Misfeld M. Surgical options in infective valve endocarditis with neurological complications. Ann Cardiothorac Surg. 2019 Nov;8(6):661-666. PMC free article: PMC6892717 PubMed: 31832356
30.Sotero FD, Rosário M, Fonseca AC, Ferro JM. Neurological Complications of Infective Endocarditis. Curr Neurol Neurosci Rep. 2019 Mar 30;19(5):23. PubMed: 30927133
31.Rajani R, Klein JL. Infective endocarditis: A contemporary update. Clin Med (Lond). 2020 Jan;20(1):31-35. PMC free article: PMC6964163 PubMed: 31941729
32.Elbatarny M, Bahji A, Bisleri G, Hamilton A. Management of endocarditis among persons who inject drugs: A narrative review of surgical and psychiatric approaches and controversies. Gen Hosp Psychiatry. 2019 Mar-Apr;57:44-49. PubMed: 30908961
Alt text: Microscopic view of a mature vegetation on a heart valve affected by infectious endocarditis, highlighting the complex structure of inflammatory cells, fibrin, platelets, and bacterial colonies.
Alt text: Echocardiogram image illustrating a vegetation (arrow) on the mitral valve, a key diagnostic finding in infectious endocarditis evaluation.
